Pharmaceutical Products: 60%
Biotechnology: 25%
Healthcare Services: 15%

Top 3 Markets:
USA: 40%
China: 35%
Europe: 15%

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, followed by biotechnology and healthcare services. The USA is the largest market for the company, followed by China and Europe. These markets benefit from strong demand for pharmaceutical solutions and innovative biotechnological products.

Production Sites: Shenzhen, China; USA; Canada

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has its main production facilities in Shenzhen, China. In addition, the company has expanded its production capacities internationally and also operates production plants in the USA and Canada. This geographical diversification enables the company to distribute its products more efficiently in global markets while benefiting from the respective regional advantages.

Focus on Biopharmaceuticals: Increase in investments in Research and Development (R&D)
International Expansion: Expansion of presence in overseas markets
Strategic Acquisitions: Acquisition of companies to expand the product portfolio

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is pursuing a multi-pronged growth strategy to strengthen its market position. A key component of this strategy is the increased investment in the research and development of biopharmaceuticals to develop and bring innovative products to the market.

Furthermore, the company plans to expand its international presence, particularly in the USA and Europe, to capitalize on market opportunities there. This will be supported by strategic partnerships and the establishment of distribution networks.

Another important aspect of the growth strategy is targeted acquisitions. By acquiring companies offering complementary technologies and products, Hepalink can expand its product portfolio and increase its market share.

Main raw materials: Heparin sodium, crude heparin

Main supplying countries: USA, Europe (especially Germany), Australia

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is known for the production of heparin and heparin-based products. The main raw material for their products is heparin sodium, which is obtained from crude heparin.

The company mainly imports crude heparin from countries with a strong livestock industry, as heparin is extracted from pig intestines. The USA and Germany are significant suppliers because they have large and well-regulated livestock populations. Australia is also an important supplier due to its high standards in animal husbandry and processing.

These international sources enable Shenzhen Hepalink to secure high-quality raw materials necessary for the production of their pharmaceutical products.

Market Share: 8% in the global heparin market (2025)
R&D Expenses: 12% of revenue (2025)
Revenue Growth: 10% (2025)

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has a significant competitive advantage in the global heparin market, where it holds a market share of 8%. This is due to its strong position in the production of heparin and related products.

The company heavily invests in research and development, with 12% of revenue allocated to R&D. These investments enable Hepalink to develop innovative products and expand its product pipeline, leading to a revenue growth of 10% in 2025.

Additionally, Hepalink benefits from an efficient supply chain and strategic partnerships that further strengthen its market position. The continuous focus on quality and cost efficiency also contributes to its competitive advantage.

Institutional Investor Share: Estimated around 30-40% (2026)

Insider Purchases/Sales: No specific current data available.

The institutional investor share in Shenzhen Hepalink Pharmaceutical Group Co., Ltd. typically ranges from 30-40%. This estimate is based on historical trends and the company's general market position.

Current data on insider purchases or sales is not specifically available. Typically, such information is disclosed in financial reports or through regulatory filings. It is advisable to consult the latest financial reports or stock exchange announcements to obtain accurate and up-to-date information.

Market share of Shenzhen Hepalink Pharmaceutical Group Co., Ltd.: Estimated around 5% (2026)

Top competitors and their market shares:

1. Sanofi (SNY): 12%
2. Pfizer (PFE): 10%
3. Boehringer Ingelheim: 8%
4. Bayer AG (BAYN): 7%
5. Roche Holding AG (ROG): 6%
6. Shenzhen Hepalink Pharmaceutical Group Co., Ltd.: 5%
7. Novo Nordisk (NOVO-B): 4%
8. AstraZeneca (AZN): 3%
9. Merck & Co., Inc. (MRK): 3%
10. Johnson & Johnson (JNJ): 2%

Moat of Shenzhen Hepalink Pharmaceutical Group Co., Ltd.:

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has a moderate moat, mainly attributed to its specialized products in the field of heparin production. The company benefits from a strong position in the supply chain for heparin, a crucial anticoagulant used in medicine worldwide.

Compared to larger international competitors like Sanofi or Pfizer, which have diversified product portfolios and extensive research and development resources, Hepalink's moat is less pronounced. These companies often have stronger market access and greater financial resources to invest in new technologies and markets.

However, Hepalink can maintain a competitive advantage through its specialization and efficiency in heparin production. Nevertheless, it is crucial for the company to continue investing in innovation and potentially diversifying its product portfolio to secure and expand its market share.

Revenue Growth: 8.5% (2025) Research and Development Expenses: 12% of revenue (2025) Market Share in Heparin Production: 30% (2025)

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. achieved a revenue growth of 8.5% in 2025, indicating stable demand for its products. The company is heavily investing in research and development, accounting for 12% of its revenue. These investments could lead to long-term innovations and a stronger market position.

Additionally, the company holds a significant market share of 30% in heparin production, indicating a strong market presence. These factors suggest that Shenzhen Hepalink is well positioned to benefit from future growth opportunities.

However, potential investors should also consider other factors such as overall market trends, regulatory changes, and the financial stability of the company before making an investment decision.

Dividend Yield: 2.5% (estimated for 2026)

Dividend History: Continuous payout over the last 5 years

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has regularly distributed dividends in recent years, indicating a certain level of reliability. The estimated dividend yield for 2026 is around 2.5%, based on past payouts and the company's financial stability.

The company has followed a policy of stable dividend payments in the past, which could be attractive to investors seeking regular returns. However, it is important to monitor the future business development and market conditions as these can affect the ability to pay dividends.